KRAS and familial pancreatic carcinoma: BI-3406, on the other hand, showed moderate therapeutic in vitro efficacy in both KRAS G12C and G12D mutated pancreatic cancer cell lines, MiaPaCa and Panc-1, respectively, in terms of reduction of clonogenicity, which was slightly more pronounced upon combination therapy with BI-3406 plus Binimetinib.